

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXJ1617

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 15:22:43 ON 26 MAR 2008
FILE 'REGISTRY' ENTERED AT 15:22:43 ON 26 MAR 2008
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	360.86	361.07

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	360.86	361.07

FILE 'REGISTRY' ENTERED AT 15:22:56 ON 26 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAR 2008 HIGHEST RN 1010115-69-1
DICTIONARY FILE UPDATES: 25 MAR 2008 HIGHEST RN 1010115-69-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10517979d.str



chain nodes :

7 8 9 10 11 12 13 14 15 16 17 18

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-8 8-9 9-10 10-11 10-13 11-12 11-14 12-15 15-16 16-17 16-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

10-13 11-14 16-17 16-18

exact bonds :

6-7 7-8 8-9 9-10 10-11 11-12 12-15 15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L8 STRUCTURE UPLOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR



Structure attributes must be viewed using STN Express query preparation.


```
=> s 18 sss sam
SAMPLE SEARCH INITIATED 15:23:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1010 TO ITERATE

100.0% PROCESSED      1010 ITERATIONS          48 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:    18294 TO    22106
PROJECTED ANSWERS:       545 TO     1375

L9      48 SEA SSS SAM L8

=>
Uploading C:\Program Files\Stnexp\Queries\10517979e.str
```



```

chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6
chain bonds :
6-7 7-8 8-9 8-22 9-10 10-11 10-13 11-12 11-14 12-15 15-16 15-21 16-17
16-18 17-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
8-22 10-13 11-14 15-21 16-17 16-18 17-20
exact bonds :
6-7 7-8 8-9 9-10 10-11 11-12 12-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```


```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom

```

L10 STRUCTURE UPLOADED

=> d 10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l10 sss sam
SAMPLE SEARCH INITIATED 15:25:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1010 TO ITERATE
```

```
100.0% PROCESSED 1010 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 18294 TO 22106
PROJECTED ANSWERS: 68 TO 532
```

```
L11 15 SEA SSS SAM L10
```

```
=> s l15 full
L15 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).
```

```
=> s l11 full
FULL SEARCH INITIATED 15:25:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18601 TO ITERATE
```


```
100.0% PROCESSED 18601 ITERATIONS 186 ANSWERS
SEARCH TIME: 00.00.01
```

L12 186 SEA SSS FUL L10

=> d 112

L12 ANSWER 1 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1005326-47-5 REGISTRY
ED Entered STN: 25 Feb 2008
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C42 H77 N3 O7 Si
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 112 2-10

L12 ANSWER 2 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 956075-59-5 REGISTRY
ED Entered STN: 27 Nov 2007
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, (γ S, δ S, ζ S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H51 N3 O3
CI COM
SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 ANSWER 3 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 956035-48-6 REGISTRY
 ED Entered STN: 27 Nov 2007
 CN Benzenoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H49 N3 O4 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (198641-63-3)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 4 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 956035-23-7 REGISTRY
 ED Entered STN: 27 Nov 2007
 CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H51 N3 O3 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (956075-59-5)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 5 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 956035-22-6 REGISTRY
ED Entered STN: 27 Nov 2007
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H50 N2 O5 S . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (198641-65-5)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 6 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 956035-21-5 REGISTRY
ED Entered STN: 27 Nov 2007
CN Acetic acid, 2-[5-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

FS STEREOSEARCH
MF C29 H50 N2 O5 . C1 H
SR CA
LC STN Files: CA, CAPLUS
CRN (198641-57-5)

Absolute stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 7 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 955083-07-5 REGISTRY
ED Entered STN: 20 Nov 2007
CN Propanoic acid, 2-[[[(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-8-methyl-2-(1-methylethyl)-1-oxononyl]amino]methyl]-2-methyl- (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H54 N2 O6
CI COM
SR CA

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 ANSWER 8 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 955032-11-8 REGISTRY
ED Entered STN: 20 Nov 2007
CN Propanoic acid, 2-[[[(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-8-methyl-2-(1-methylethyl)-1-oxononyl]amino]methyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H54 N2 O6 . C1 H
SR CA

LC STN Files: CA, CAPLUS, CASREACT
CRN (955083-07-5)

Absolute stereochemistry.




● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 9 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 909406-48-0 REGISTRY
ED Entered STN: 03 Oct 2006
CN Benzeneoctanamide, 4-acetyl- δ -amino- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furanyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C31 H52 N2 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 10 OF 186 REGISTRY COPYRIGHT 2008 ACS on STN
RN 909406-46-8 REGISTRY
ED Entered STN: 03 Oct 2006

CN Benzenoctanamide, 8-amino-4-(1,1-difluoroethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α,ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furanyl]methyl-, (aS, γ S,8S, ζ S)- (9CI) (CA INDEX
NAME)


FS STEREOSEARCH

MF C31 H52 F2 N2 O5

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY TOTAL

FULL ESTIMATED COST

200.66

SESSION

561.73

FILE 'HCAPLUS' ENTERED AT 15:26:38 ON 26 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Mar 2008 VOL 148 ISS 13

FILE LAST UPDATED: 25 Mar 2008 (20080325/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 112

L13 9 L12

=> d 113 ibib abs hitstr

L13 ANSWER 1 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1003206 HCPLUS
DOCUMENT NUMBER: 147:502612
TITLE: Novel 2,7-Dialkyl-Substituted 5(S)-Amino-4(S)-hydroxy-8-phenyl-octanecarboxamide Transition State Peptidomimetics Are Potent and Orally Active Inhibitors of Human Renin
AUTHOR(S): Goeschke, Richard; Stutz, Stefan; Rasetti, Vittorio; Cohen, Nissim-Claude; Rahuel, Joseph; Rigollier, Pascal; Baum, Hans-Peter; Forgiarini, Peter; Schnell, Christian R.; Wagner, Trixie; Gruetter, Markus G.; Fuhrer, Walter; Schilling, Walter; Cumin, Frederic; Wood, Jeanette M.; Maibaum, Juergen
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, NOVARTIS Pharma AG, Basel, CH-4002, Switz.
SOURCE: Journal of Medicinal Chemistry (2007), 50(20), 4818-4831
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:502612
GI



AB The action of renin is the rate-limiting step of the renin-angiotensin system (RAS), a key regulator of blood pressure. Effective renin inhibitors directly block the RAS entirely at source and, thus, may provide a vital weapon for hypertension therapy. The efforts made by authors toward identifying novel small-mol. peptidomimetic renin inhibitors have resulted in the design of transition-state isosteres such as peptidomimetic I bearing an all-carbon 8-phenyl-octanecarboxamide framework. Optimization of the extended P3 portion of I and extensive P2' modifications provided analogs with improved *in vitro* potencies in the presence of plasma. X-ray resolution of rh-renin complex with newly-synthesized peptidomimetic II in the course of SAR work surprisingly unveiled the exploitation of a previously unexplored pocket (S3sp)

important for strong binding affinities. Several inhibitors demonstrated oral efficacy in sodium-depleted marmosets. II, the most potent inhibitor, induced dose-dependently a pronounced reduction in mean arterial blood pressure, paralleled by complete blockade of active plasma renin, up to 8 post-dose. Oral bioavailability of II was 16% in marmosets.


IT 173399-37-6

RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and biol. activity of peptidomimetics as renin inhibitors)

RN 173399-37-6 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 956035-21-5P 956035-22-6P 956035-23-7P


956035-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of peptidomimetics as renin inhibitors)

RN 956035-21-5 HCPLUS

CN Acetic acid, 2-[5-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-22-6 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-23-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-48-6 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl



REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l13 ibib abs hitstr 1-9

L13 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1003206 HCAPLUS
DOCUMENT NUMBER: 147:502612
TITLE: Novel 2,7-Dialkyl-Substituted 5(S)-Amino-4(S)-hydroxy-
8-phenyl-octanecarboxamide Transition State
Peptidomimetics Are Potent and Orally Active
Inhibitors of Human Renin
AUTHOR(S): Goeschke, Richard; Stutz, Stefan; Rasetti, Vittorio;
Cohen, Nissim-Claude; Rahuel, Joseph; Rigollier,
Pascal; Baum, Hans-Peter; Forgiarini, Peter; Schnell,
Christian R.; Wagner, Trixie; Gruetter, Markus G.;
Fuhrer, Walter; Schilling, Walter; Cumin, Frederic;
Wood, Jeanette M.; Maibaum, Juergen
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, NOVARTIS
Pharma AG, Basel, CH-4002, Switz.
SOURCE: Journal of Medicinal Chemistry (2007), 50(20),
4818-4831
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:502612
GI



AB The action of renin is the rate-limiting step of the renin-angiotensin system (RAS), a key regulator of blood pressure. Effective renin inhibitors directly block the RAS entirely at source and, thus, may provide a vital weapon for hypertension therapy. The efforts made by authors toward identifying novel small-mol. peptidomimetic renin inhibitors have resulted in the design of transition-state isosteres such as peptidomimetic I bearing an all-carbon 8-phenyl-octanecarboxamide framework. Optimization of the extended P3 portion of I and extensive P2' modifications provided analogs with improved *in vitro* potencies in the presence of plasma. X-ray resolution of rh-renin complex with newly-synthesized peptidomimetic II in the course of SAR work surprisingly unveiled the exploitation of a previously unexplored pocket (S3sp)

important for strong binding affinities. Several inhibitors demonstrated oral efficacy in sodium-depleted marmosets. II, the most potent inhibitor, induced dose-dependently a pronounced reduction in mean arterial blood pressure, paralleled by complete blockade of active plasma renin, up to 8 post-dose. Oral bioavailability of II was 16% in marmosets.


IT 173399-37-6

RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and biol. activity of peptidomimetics as renin inhibitors)

RN 173399-37-6 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 956035-21-5P 956035-22-6P 956035-23-7P


956035-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of peptidomimetics as renin inhibitors)

RN 956035-21-5 HCPLUS

CN Acetic acid, 2-[5-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-22-6 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-23-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 956035-48-6 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, hydrochloride (1:1), (γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl


REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1003125 HCPLUS
DOCUMENT NUMBER: 147:496157
TITLE: Structural Modification of the P2' Position of
2,7-Dialkyl-Substituted 5(S)-Amino-4(S)-hydroxy-8-
phenyl-octanecarboxamides: The Discovery of Aliskiren,
a Potent Nonpeptide Human Renin Inhibitor Active after
Once Daily Dosing in Marmosets
AUTHOR(S): Maibaum, Juergen; Stutz, Stefan; Goeschke, Richard;
Rigollier, Pascal; Yamaguchi, Yasuchika; Cumin,
Frederic; Rahuel, Joseph; Baum, Hans-Peter; Cohen,
Nissim-Claude; Schnell, Christian R.; Fuhrer, Walter;
Gruetter, Markus G.; Schilling, Walter; Wood, Jeanette
M.
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, NOVARTIS
Pharma AG, Basel, CH-4002, Switz.
SOURCE: Journal of Medicinal Chemistry (2007), 50(20),
4832-4844
PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: American Chemical Society
LANGUAGE: Journal
OTHER SOURCE(S): English
CASREACT 147:496157
AB Due to its function in the rate limiting initial step of the
renin-angiotensin system, renin is a particularly promising target for
drugs designed to control hypertension, a growing risk to health
worldwide. Despite vast efforts over more than two decades, no orally
efficacious renin inhibitor had reached the market. As a result of a
structure-based topol. design approach, we have identified a novel class
of small-mol. inhibitors with good oral blood-pressure lowering effects in
primates. Further lead optimization aimed for improvement of in vivo
potency and duration of action, mainly by P2' modifications at the
hydroxyethylene transition-state isostere. These efforts resulted in the
discovery of aliskiren (46, CGP060536B, SPP100), highly potent,
selective inhibitor of renin, demonstrating excellent efficacy in
sodium-depleted marmosets after oral administration, with sustained
duration of action in reducing dose-dependently mean arterial blood
pressure. Aliskiren has recently received regulatory approval by the U.S.
Food and Drug Administration for the treatment of hypertension.
IT 173335-48-3P 955032-11-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
RN (dialkyl-substituted amino-hydroxy-Ph octanecarboxamides: preparation and
renin inhibition)
RN 173335-48-3 HCPLUS
CN Benzeneoctanamide, 8-amino- γ -hydroxy-4-methoxy-3-(4-
methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-
, hydrochloride (1:2), (α S, δ S, γ S, ζ S)- (CA INDEX
NAME)


Absolute stereochemistry.



● 2 HCl

RN 955032-11-8 HCPLUS
 CN Propanoic acid, 2-[[[(2S,4S,5S,7S)-5-amino-4-hydroxy-7-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-8-methyl-2-(1-methylethyl)-1-oxononyl]amino]methyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 173336-72-6P 173338-39-1P 1005326-47-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (dialkyl-substituted amino-hydroxy-Ph octanecarboxamides: preparation and renin inhibition)
 RN 173336-72-6 HCPLUS
 CN Carbanic acid, N-[(1S,2S,4S)-2-hydroxy-1-[(2S)-2-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-3-methylbutyl]-5-methyl-4-[[2-(4-morpholinyl)ethyl]amino]carbonyl]hexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173338-39-1 HCAPLUS

CN Carbamic acid, N-[1S,2S,4S]-4-[[[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-2-hydroxy-1-[(2S)-2-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-3-methylbutyl]-5-methylhexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1005326-47-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT:

54

THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L13 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:944794 HCAPLUS

DOCUMENT NUMBER: 145:314826
 TITLE: Preparation of (N-heterocyclyl) 5-amino-7-benzyl-4-hydroxy-2-isopropyl-8-methylnonanamides as renin inhibitors
 INVENTOR(S): Herold, Peter; Mah, Robert; Tschinke, Vincenzo; Stutz, Stefan; Behnke, Dirk; Stojanovic, Aleksandar; Jelakovic, Stjepan; Marti, Christiane
 PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.
 SOURCE: PCT Int. Appl., 79pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006095020	A1	20060914	WO 2006-EP60625	20060310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2600674	A1	20060914	CA 2006-2600674	20060310
EP 1856032	A1	20071121	EP 2006-725011	20060310
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN07256	A	20071026	IN 2007-DN7256	20070920
PRIORITY APPLN. INFO.:			CH 2005-427	A 20050311
			CH 2005-1522	A 20050917
			WO 2006-EP60625	W 20060310


OTHER SOURCE(S): MARPAT 145:314826
 GI



AB Title compds. [I; R1 = (substituted) azepanyl, azetidinyl, aziridinyl, dioxanyl, dioxepanyl, dioxolanyl, dithianyl, dithiolanyl, furyl, oxathianyl, tetrahydropyranyl, thiepanyl, substituted alkynyl, etc.; R2 = (substituted) alkanoyl, alkanoylalkoxy, alkanylaminooalkyl, alkylpiperazinylalkoxy, carbamoylalkyl, piperazinooalkyl, Ph, naphthyl, etc.], were prepared. Thus, 5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanoic acid (1-methylpiperidin-4-yl)amide was prepared starting from 5-[1-azido-3-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methylpentyl]-3-isopropylidihydrofuran-2-one and 1-methylpiperidin-4-ylamine. I inhibited renin in vitro in the range


IT 10-6-10-10 M.
 909406-36-6P 909406-39-9P 909406-40-2P
 909406-46-8P 909406-48-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of (N-heterocyclyl) aminobenzylhydroxyisopropylmethylnonanamide
 as renin inhibitors)
 RN 909406-36-6 HCAPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-3-(3-methoxypropoxy)-4-
 methyl- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-
 furanyl]methyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 909406-39-9 HCPLUS
CN Benzenoectanamide, 8-amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furanyl]methyl]-, (as,rs,ss,ss)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 909406-40-2 HCAPLUS
CN Benzenoctanamide, δ -amino-3-ethyl- γ -hydroxy-4-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 909406-46-8 HCPLUS
 CN Benzeneoctanamide, δ -amino-4-(1,1-difluoroethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furanyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 909406-48-0 HCPLUS
 CN Benzeneoctanamide, 4-acetyl- δ -amino- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-N-[(2S)-tetrahydro-2-furanyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:991334 HCPLUS
 DOCUMENT NUMBER: 140:41913
 TITLE: Methods of treating Alzheimer's disease using and method of preparing δ -amino- γ -hydroxy- α -arylalkanoic acid amides
 INVENTOR(S): John, Varghese; Maillard, Michel

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 363 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103653	A1	20031218	WO 2003-US18517	20030611
WO 2003103653	A8	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238007	A1	20031222	AU 2003-238007	20030611
US 2006154926	A1	20060713	US 2005-517979	20051219
PRIORITY APPLN. INFO.:				
US 2002-387880P				
WO 2003-US18517				
P 20020611				
W 20030611				

OTHER SOURCE(S): MARPAT 140:41913
 GI



AB Disclosed are methods for treating Alzheimer's disease (no data), and other diseases (no data), and/or inhibiting beta-secretase enzyme (no data), and/or inhibiting deposition of A beta peptide in a mammal (no data), using δ -amino- γ -hydroxy- α -arylalkanoic acid amides (shown as I; variables defined below; e.g. 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride). For I: R1 = H, OH, alkoxy, cycloalkoxy, alkoxyalkoxy, free or amidated or esterified carboxy-alkoxy; R2 = H, alkyl, cycloalkyl, alkoxyalkyl, cycloalkoxyalkyl, OH, hydroxyalkoxy, heteroarylalkyl, etc.; R3 = halogenated alkyl, alkoxyalkyl, hydroxyalkyl, optionally S-oxidized alkylthioalkyl, etc.; R4 = H, alkyl, OH, alkoxy, cycloalkoxy; X = CH2; R5 = alkyl, cycloalkyl; R6 = unsubstituted or alkylated or alkanoylated amino; R7 = alkyl, alkenyl, cycloalkyl, aralkyl; R8 = alkyl, cycloalkyl, free or esterified or etherified hydroxyalkyl, free or esterified or amidated carboxyalkyl, etc. Although the methods of preparation are claimed and >180 example preps. are included, these examples comprise an English translation of a German patent (EP 678503; 1995; CA

file accession number 1995:995373). Thus, 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylamide hydrochloride was prepared in several steps starting with 3-isovaleryl-4(R)-benzylloxazolidin-2-one and p-tert-butylbenzyl bromide.


IT 172900-93-5P 173007-35-7P 173154-08-0P
173333-96-5P 173333-98-7P 173333-99-8P
173334-00-4P 173334-01-5P 173334-02-6P
173334-03-7P 173334-04-8P 173334-05-9P
173334-06-0P 173334-07-1P 173334-08-2P
173334-09-3P 173334-10-6P 173334-11-7P
173334-12-8P 173334-13-9P 173334-14-0P
173334-15-1P 173334-16-2P 173334-17-3P
173334-18-4P 173334-19-5P 173334-20-8P
173334-37-7P 173334-38-8P 173334-59-3P
173335-47-2P 173335-48-3P 173335-49-4P
173335-51-8P 173335-52-9P 173335-53-0P
173335-54-1P 173335-56-3P 173335-57-4P
173335-62-1P 173335-74-5P 173335-86-9P
173335-92-7P 173398-83-9P 173398-84-0P
173398-85-1P 173398-86-2P 173398-87-3P
173398-88-4P 173398-89-5P 173398-90-8P
173398-91-9P 173398-92-0P 173398-93-1P
173398-94-2P 173398-95-3P 173398-96-4P
173398-97-5P 173398-98-6P 173398-99-7P
173399-00-3P 173399-01-4P 173399-21-8P
173399-24-1P 173399-25-2P 173399-26-3P
173399-27-4P 173399-30-9P 173399-31-0P
173399-32-1P 173399-33-2P 173399-34-3P
173399-35-4P 173399-36-5P 173399-37-6P
173399-38-7P 173399-39-8P 173399-40-1P
173399-41-2P 173399-43-4P 173399-44-5P
173399-45-6P 173399-46-7P 173399-47-8P
173399-48-9P 173399-49-0P 173399-66-1P
173399-67-2P 173400-31-2P 173400-32-3P
173400-35-6P 173521-16-9P 173521-17-0P
173521-18-1P 173521-19-2P 173521-20-5P
173521-21-6P 173521-22-7P 173521-23-8P
173521-24-9P 173521-25-0P 173521-26-1P
173521-27-2P 173521-28-3P 173521-29-4P
173521-30-7P 173521-31-8P 173521-32-9P
173521-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods of treating Alzheimer's disease using and method of preparing δ -amino- γ -hydroxy- α -arylalkanoic acid amides)

RN 172900-93-5 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HC1

BN 173007-35-7 HCAPLUS

CN Benzeno-octanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (aS, yS, 8S, 8S, CS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HC1

RN 173154-08-0 HCAPLUS

CN Benzeneoctanamide, 8-amino-N-butyl- γ -hydroxy-4-methoxy-3-[2-(methoxymethyl)ethyl]-, α -, ζ -bis(1-methylethyl)-, (aS, yS, zS, CS)- (5CI) (CA INDEX NAME)


Absolute stereochemistry.



BN 173333-96-5 HCABLIJS

AN 173535-98-5 ACIFLUO
 CN Benzenoecotanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, monohydrochloride,
 (a.R.v.S.8S.CS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173333-98-7 HCPLUS
 CN 2-Naphthaleneoctanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, monohydrochloride,
 $(\alpha R, \gamma S, \delta S, \zeta S)$ - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173333-99-8 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,3-dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride,
 $(\alpha R, \gamma S, \delta S, \zeta S)$ - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-00-4 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride,
 $(\alpha R, \gamma S, \delta S, \zeta S)$ - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-01-5 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-02-6 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-propenyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-03-7 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2R,4R,5R,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




● HCl

RN 173334-04-8 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxoethyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-05-9 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-06-0 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-07-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-08-2 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-09-3 HCPLUS
 CN 2-Propenoic acid, 2-[(5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-10-6 HCPLUS
 CN Butanoic acid, 4-[(5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-11-7 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -

hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-12-8 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-13-9 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-14-0 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3-

dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-15-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-16-2 HCPLUS

CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-17-3 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-3-(3-chloro-2-hydroxypropoxy)-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 173334-18-4 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylthio)propoxy]- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 173334-19-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -

hydroxy-3-[2-hydroxy-3-(methylsulfonyl)propoxy]- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 173334-20-8 HCPLUS

CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-N-[3-(4-morpholinyl)propyl]-, monohydrochloride, (α R, γ S, δ S,.zeta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-37-7 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-38-8 HCPLUS
 CN Benzoic acid, 2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-59-3 HCPLUS
 CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α, ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride, ($\alpha S, \gamma S, \delta S, \zeta S$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 173335-47-2 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-
 γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173335-48-3 HCPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, hydrochloride (1:2), (α S, δ S, γ S, ζ S)- (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 173335-49-4 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl- γ , η -dihydroxy-4-methoxy-3-(2-(methoxymethoxy)ethyl)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S, η R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 173335-51-8 HCPLUS
 CN Propanoic acid, 3-[5-(4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 173335-52-9 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-3-(3-chloro-2-hydroxypropoxy)-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)- (CA INDEX NAME)



RN 173335-53-0 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylthio)propoxy]- α -methyl- ζ -(1-methylethyl)- (CA INDEX NAME)




RN 173335-54-1 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylsulfonyl)propoxyl- α -methyl- ζ -(1-methylethyl)- (CA INDEX NAME)




RN 173335-56-3 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ ,4-tris(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173335-57-4 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173335-62-1 HCAPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-3-(3-methoxypropoxy)-4-(4-(methylamino)-4-oxobutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 173335-74-5 HCPLUS

CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[(2S)-5-oxo-2-pyrrolidinyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173335-86-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-[(1,6-dihydro-6-oxo-2-pyridinyl)methyl]- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173335-92-7 HCAPLUS

CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(4-methoxy-1-butenyl)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 173398-83-9 HCAPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-84-0 HCAPLUS

CN 2-Naphthaleneoctanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

RN 173398-85-1 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (aS, yS, δ S, ζ S) - (5CI) (CA INDEX NAME)


Absolute stereochemistry.



• HC1

RN 173398-86-2 HCPLUS
CN 2-Butenoic acid, 4-[5-[(2R,4R,5R,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



• HCl

RN 173398-87-3 HCPLUS
CN Acetic acid, [5-[1(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-1-
(1-methylethyl)-8-oxoocetyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-88-4 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-89-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-90-8 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, monohydrochloride, (α S, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-91-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-92-0 HCPLUS
 CN 2-Propenoic acid, 2-[(5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-93-1 HCPLUS
 CN Butanoic acid, 4-[(5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-94-2 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -

hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-95-3 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-96-4 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-97-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-

dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-98-6 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-99-7 HCPLUS

CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173399-00-3 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173399-01-4 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 173399-21-8 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl- γ , η -dihydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-,
($\alpha S, \gamma S, \delta S, \zeta S, nS$) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-24-1 HCAPLUS
 CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α -, ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, (aS, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 173399-25-2 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α R, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-26-3 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -

hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-27-4 HCAPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (aR, γ S, 8S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-30-9 HCAPLUS

CN 2-Naphthaleneoctanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, (aR, γ S, 8S, .ze ta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-31-0 HCAPLUS

CN Benzenoectanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,3-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, yS, δ S, ζ S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-32-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-33-2 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-34-3 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-propenyoxy)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-35-4 HCPLUS


CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 173399-36-5 HCPLUS
CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-37-6 HCPLUS
CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α R, γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-38-7 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



RN 173399-41-2 HCPLUS

CN 2-Propenoic acid, 2-[(5-[2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-43-4 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-44-5 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-45-6 HCPLUS


CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-46-7 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-47-8 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173399-48-9 HCPLUS
 CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-49-0 HCPLUS

CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-N-[3-(4-morpholinyl)propyl]-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-66-1 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-67-2 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-31-2 HCPLUS

CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, (aS, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-32-3 HCPLUS

CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-35-6 HCPLUS

CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[(2R)-5-oxo-2-pyrrolidinyl]methyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-16-9 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-17-0 HCPLUS
 CN 2-Naphthaleneoctanamide, 8-amino-N-butyl-5-ethyl-5-hydroxy-5-methyl-4-(propoxymethyl)-, (alphaS, gammaS, deltaS, .ze ta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-18-1 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)-5-dihydroxy-5-methyl-5-((1-methylethyl)-, (alphaS, gammaS, deltaS, zetaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-19-2 HCPLUS
 CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 173521-20-5 HCPLUS
CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-21-6 HCPLUS
CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-22-7 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173521-23-8 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-24-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-25-0 HCPLUS

CN 2-Propenoic acid, 2-[(5-[(2S,4S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-26-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-27-2 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-28-3 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-29-4 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-30-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-31-8 HCPLUS

CN Benzenesoctanamide, 8-amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (aS, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-32-9 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-33-0 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 172900-94-6P 173336-00-0P 173336-05-5P
173336-08-8P 173336-09-9P 173336-10-2P
173336-11-3P 173336-24-8P 173336-72-6P
173336-73-7P 173337-05-8P 173337-09-2P
173337-10-5P 173337-11-6P 173337-12-7P
173337-13-8P 173337-14-9P 173337-15-0P
173337-16-1P 173337-17-2P 173337-18-3P
173337-19-4P 173337-20-7P 173337-21-8P
173337-22-9P 173337-23-0P 173337-24-1P
173338-39-1P 173400-41-4P 173400-42-5P
173400-43-6P 173400-47-0P 173400-48-1P
173400-49-2P 173400-50-5P 173400-51-6P
173400-52-7P 173400-53-8P 173400-54-9P
173400-55-0P 173400-56-1P 173400-57-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treating Alzheimer's disease using and method of preparing 8-amino- γ -hydroxy- α -arylkanoic acid amides)

RN 172900-94-6 HCPLUS

CN Carbanic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-00-0 HCPLUS

CN Carbanic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-05-5 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-2-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-08-8 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-09-9 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylthio)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-10-2 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-11-3 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2S)-2-hydroxy-3-(methylthio)propoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-24-8 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(methoxypropoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-5-methyl-4-[[2-(4-morpholinyl)ethyl]amino]carbonyl]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-72-6 HCPLUS

CN Carbamic acid, N-[(1S,2S,4S)-2-hydroxy-1-[(2S)-2-[[4-methoxy-3-(4-methoxybutyl)phenyl]methyl]-3-methylbutyl]-5-methyl-4-[[2-(4-morpholinyl)ethyl]amino]carbonyl]hexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-73-7 HCPLUS

CN Benzeneoctanamide, 8-azido-N-butyl- γ , η -dihydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-, (aS, γ S, δ S, ζ S, η R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-05-8 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-

dimethyllethyl)phenyl]methyl]butyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethyllethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-09-2 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethyllethyl)-3-(2-propenyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethyllethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-10-5 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethyllethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethyllethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173337-11-6 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethyllethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethyllethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-12-7 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(3-(2-amino-2-oxoethoxy)-4-(1,1-dimethylethyl)phenyl]methyl]-3-methylbutyl]-5-(butylamino)-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-13-8 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(2-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-14-9 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(4-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-15-0 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-16-1 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[[((1,1-dimethylethoxy)carbonyl)amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173337-17-2 HCPLUS

CN Butanoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxo-4-oxo-4,5-dihydro-1H-1,3-dioxolane-2-yl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-18-3 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxo-4-oxo-4,5-dihydro-1H-1,3-dioxolane-2-yl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-19-4 HCPLUS


CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2-nitrophenyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-20-7 HCAPLUS

CN Carbamic acid, [5-(butylamino)-1-[2-[(4-(1,1-dimethylethyl)-3-(oxiranylmethoxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 173337-21-8 HCAPLUS

CN 21595-21-6 (CN1268)
 Carbamic acid, [5-(butylamino)-1-[2-[(4-(1,1-dimethylethyl)-2-(2-hydroxyproxy)-3-(methylsulfonyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 173337-22-9 HCAPLUS

CN Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-


5-[(3-(4-morpholinyl)propyl)amino]-5-oxopentyl-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-23-0 HCPLUS
 CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-24-1 HCPLUS
 CN Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-[(3-(4-morpholinyl)propyl)amino]-5-oxopentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173338-39-1 HCPLUS
 CN Carbamic acid, N-[(1S,2S,4S)-4-[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-2-hydroxy-1-[(2S)-2-[(4-methoxy-3-(4-methoxybutyl)phenyl)methyl]-3-methylbutyl]-5-methylhexyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-41-4 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(methylthio)methoxy]phenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-42-5 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-43-6 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(2R)-2-hydroxy-3-(methylthio)propoxylphenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-47-0 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 173400-48-1 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-49-2 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-1-[(2S)-2-[(3-(2-amino-2-oxoethoxy)-4-(1,1-dimethylethyl)phenyl)methyl]-3-methylbutyl]-5-(butylamino)-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-50-5 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(2-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-51-6 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(4-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-52-7 HCAPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173400-53-8 HCAPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173400-54-9 HCPLUS

CN Butanoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-55-0 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2-nitrophenyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-56-1 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-57-2 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1645757 HCPLUS

DOCUMENT NUMBER: 139:301694

TITLE: Structure-based design of aliskiren, a novel orally effective renin inhibitor

AUTHOR(S): Wood, Jeanette M.; Maibaum, Juergen; Rahuel, Joseph; Gruetter, Markus G.; Cohen, Nissim-Claude; Rasetti, Vittorio; Rueger, Heinrich; Goeschke, Richard; Stutz, Stefan; Fuhrer, Walter; Schilling, Walter; Rigollier, Pascal; Yamaguchi, Yasuchika; Cumin, Frederic; Baum, Hans-Peter; Schnell, Christian R.; Herold, Peter; Mah, Robert; Jensen, Chris; O'Brien, Eoin; Stanton, Alice; Bedigian, Martin P.

CORPORATE SOURCE: Novartis Institute for Biomedical Research, Basel, CH-4002, Switz.

SOURCE: Biochemical and Biophysical Research Communications (2003), 308(4), 698-705

CODEN: BBRCA9; ISSN: 0006-291X

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of the renin-angiotensin system (RAS) have proven to be successful treatments for hypertension. As renin specifically catalyzes the rate-limiting step of the RAS, it represents the optimal target for RAS inhibition. Several peptide-like renin inhibitors have been synthesized previously, but poor pharmacokinetic

properties meant that these compds. were not clin. useful. We employed a combination of mol. modeling and crystallog. structure anal. to design renin inhibitors lacking the extended peptide-like backbone of earlier inhibitors, for improved pharmacokinetic properties. This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients. Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.


IT 173399-36-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-based design of renin inhibitor aliskiren for treatment of hypertension)

RN 173399-36-5 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:741257 HCPLUS

DOCUMENT NUMBER: 127:359067

TITLE: Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin

AUTHOR(S): Boschke, Richard; Cohen, Nissim Claude; Wood, Jeanette M.; Maibaum, Jurgen

CORPORATE SOURCE: Metabolic Cardiovascular Diseases, Novartis Pharma AG, Basel, CH-4002, Switz.


SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(21), 2735-2740

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Novel low-mol. weight transition-state peptidomimetic renin inhibitors I (R2 = Me, Et, CHMe2, CH2CHMe2, CMe3, Ph; R3 = H, Ph, CMe3; R4 = H, OH, OBu, OCH2CH:CH2, OCH2CO2Me, OCH2CO2H, OCH2CONH2, OCH2SO2Me; R5 = H, OCH2CO2Et), characterized by an all-carbon 8-Ph substituted octane-carboxamide skeleton have been discovered based on a topog. design approach. The in vitro most potent inhibitors I (R2 = CHMe2, R3 = CMe3, R5 = H; R4 = OCH2CO2Me, OCH2CONH2, OCH2SO2Me), incorporating a strong H-bond acceptor group linked to the benzyl spacer of the (P3-P1)-unit had IC50 values in the low nanomolar range against human renin.

IT 173399-31-0P 173399-34-3P 198641-47-3P
 198641-48-4P 198641-50-8P 198641-51-9P
 198641-52-0P 198641-53-1P 198641-55-3P
 198641-57-5P 198641-58-6P 198641-61-1P
 198641-63-3P 198641-65-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design and preparation of substituted amino(hydroxy)phenyloctanecarboxamide peptidomimetics as potent human renin inhibitors)

RN 173399-31-0 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,3-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-34-3 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-propenyl)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198641-47-3 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α , ζ -dimethyl-, (γ S, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198641-48-4 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (γ S, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198641-50-8 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (γ S, δ S, ζ R)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198641-51-9 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (γ S, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-52-0 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(2-methylpropyl)-, (math>\gammaS, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-53-1 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl- ζ ,4-bis(1,1-dimethylethyl)- γ -hydroxy- α -methyl-, (math>\gammaS, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-55-3 HCPLUS

CN Benzeneoctanamide, 8-amino-3-butoxy-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (math>\gammaS, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-57-5 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-58-6 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-61-1 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-63-3 HCPLUS

CN Benzeneoctanamide, δ-amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)-γ-hydroxy-α-methyl-ζ-(1-methylethyl)-, (γS,δS,ζS)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-65-5 HCPLUS

CN Benzenoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (γ S, δ S, ζ S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 198641-74-6P 198641-75-7P 198641-76-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design and preparation of substituted amino(hydroxy)phenyloctanecarboxamide peptidomimetics as potent human renin inhibitors)

RN 198641-74-6 HCPLUS

CN Carbamic acid, [(1S,2S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-75-7 HCPLUS

CN Carbamic acid, [(1S,2S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(2-propenyl)oxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198641-76-8 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 19951995373 HCPLUS
 DOCUMENT NUMBER: 124:201791
 TITLE: Preparation of δ -amino- γ -hydroxy- ω -arylalkanoic acid amides as renin inhibitors.
 INVENTOR(S): Goeschke, Richard; Maibaum, Juergen Klaus; Schilling, Walter; Stutz, Stefan; Rigollier, Pascal; Yamaguchi, Yasuchika; Cohen, Nissim Claude; Herold, Peter
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 115 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678503	A1	19951025	EP 1995-810236	19950407
EP 678503	B1	19990901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5559111	A	19960924	US 1995-416242	19950404
AT 183997	T	19990915	AT 1995-810236	19950407
ES 2137478	T3	19991216	ES 1995-810236	19950407
FI 9501771	A	19951019	FI 1995-1771	19950412
FI 118336	B1	20071015		
NO 9501441	A	19951019	NO 1995-1441	19950412
NO 310410	B1	200110702		
AU 9516421	A	19951026	AU 1995-16421	19950412
AU 699616	B2	19981210		
ZA 9503051	A	19951018	ZA 1995-3051	19950413
ZA 9503052	A	19951018	ZA 1995-3052	19950413
CA 2147056	A1	19951019	CA 1995-2147056	19950413
CA 2147056	C	20051025		
ZA 9503050	A	19951108	ZA 1995-3050	19950413
HU 71701	A2	199610129	HU 1995-1078	19950414
HU 74074	A2	19961028	HU 1995-1076	19950414
CZ 287935	B6	200101314	CZ 1995-976	19950414
TW 402582	B	20000821	TW 1995-84103732	19950415
CN 1117960	A	19960306	CN 1995-105037	19950417
IL 113403	A	200101724	IL 1995-113403	19950417
CN 1550491	A	20041201	CN 2004-10034682	19950417
JP 08081430	A	19960326	JP 1995-92532	19950418
JP 3240322	B2	20011217		
US 5654445	A	19970805	US 1996-674555	19960702
US 5627182	A	19970506	US 1996-687878	19960725

US 5646143	A	19970708	US 1996-687277	19960725
US 5705658	A	19980106	US 1997-800671	19970214
GR 3031997	T3	20000331	GR 1999-403090	19991130
HK 1070881	A1	20070119	HK 2005-103691	20050429
PRIORITY APPLN. INFO.:		CH 1994-1169	A 19940418	
		US 1995-416242	A3 19950404	
		US 1996-687277	A3 19960725	

OTHER SOURCE(S): MARPAT 124:201791
GI



AB Title compds. [I; R1 = H, OH, alkoxy, cycloalkoxy, alkoxyalkoxy, (amidated or esterified) CO2H; R2 = H, alkyl, cycloalkyl, alkoxyalkyl, cycloalkoxyalkyl, OH, hydroxyalkoxy, heteroarylalkyl, etc.; R3 = (halogenated) alkyl, alkoxyalkyl, hydroxyalkyl, (S-oxidized) alkylthioalkyl, etc.; R4 = H, alkyl, OH, alkoxy, cycloalkoxy; R3R4 = alkylenedioxy, condensed benzo- or cyclohexeno ring; X = CH2, CHO; R5 = alkyl, cycloalkyl, aralkyl; R6 = (alkylated alkanoylated) amino; R7 = alkyl, alkenyl, cycloalkyl, aralkyl; R8 = alkyl, cycloalkyl, (esterified or etherified) hydroxyalkyl, (esterified or amidated) carboxyalkyl, etc.], were prepared. Thus, 2(R,S)-methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)octanoic acid N-butylanide hydrochloride was prepared in several steps starting with 3-isovaleryl-4(R)-benzyloxazolidin-2-one and p-tert-butylbenzyl bromide. I inhibited human plasma renin with IC50 = 10-6-10-10 M, and reduced blood pressure in marmosets at 0.003-0.3 mg/kg i.v.

IT 172900-93-5P 173007-35-7P 173154-08-0P
 173333-96-5P 173333-98-7P 173333-99-8P
 173334-00-4P 173334-01-5P 173334-02-6P
 173334-03-7P 173334-04-8P 173334-05-9P
 173334-06-0P 173334-07-1P 173334-08-2P
 173334-09-3P 173334-10-6P 173334-11-7P
 173334-12-8P 173334-13-9P 173334-14-0P
 173334-15-1P 173334-16-2P 173334-17-3P
 173334-18-4P 173334-19-5P 173334-20-8P
 173334-37-7P 173334-38-8P 173334-59-3P
 173335-47-2P 173335-48-3P 173335-49-4P
 173335-51-8P 173335-52-9P 173335-53-0P
 173335-54-1P 173335-56-3P 173335-57-4P
 173335-62-1P 173335-74-5P 173335-86-9P
 173335-92-7P 173398-83-9P 173398-84-0P
 173398-85-1P 173398-86-2P 173398-87-3P
 173398-88-4P 173398-89-5P 173398-90-8P
 173398-91-9P 173398-92-0P 173398-93-1P
 173398-94-2P 173398-95-3P 173398-96-4P
 173398-97-5P 173398-98-6P 173398-99-7P
 173399-00-3P 173399-01-4P 173399-21-8P
 173399-24-1P 173399-25-2P 173399-26-3P
 173399-27-4P 173399-30-9P 173399-31-0P


173399-32-1P 173399-33-2P 173399-34-3P
 173399-35-4P 173399-36-5P 173399-37-6P
 173399-38-7P 173399-39-8P 173399-40-1P
 173399-41-2P 173399-43-4P 173399-44-5P
 173399-45-6P 173399-46-7P 173399-47-8P
 173399-48-9P 173399-49-0P 173399-66-1P
 173399-67-2P 173400-31-2P 173400-32-3P
 173400-35-6P 173521-16-9P 173521-17-0P
 173521-18-1P 173521-19-2P 173521-20-5P
 173521-21-6P 173521-22-7P 173521-23-8P
 173521-24-9P 173521-25-0P 173521-26-1P
 173521-27-2P 173521-28-3P 173521-29-4P
 173521-30-7P 173521-31-8P 173521-32-9P
 173521-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of δ -amino- γ -hydroxy- α -aryalkanoic acid amides as renin inhibitors)

RN 172900-93-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173007-35-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173154-08-0 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-gamma-hydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]-alpha,zeta-bis(1-methylethyl)-,

($\alpha S, \gamma S, \delta S, \zeta S$) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173333-96-5 HCAPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, monohydrochloride, (aR, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173333-98-7 HCAPLUS

CN 2-Naphthaleneoctanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 173333-99-8 HCAPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ , γ -dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-00-4 HCPLUS

CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-01-5 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-02-6 HCPLUS

CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-propenyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-03-7 HCPLUS
 CN 2-Butenoic acid, 4-[5-[(2R,4R,5R,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



● HCl

RN 173334-04-8 HCPLUS
 CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-05-9 HCPLUS
 CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-06-0 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-07-1 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-08-2 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridyl)methoxy], monohydrochloride, (α R, γ S, δ S, ζ S)- (SCI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-09-3 HCPLUS
CN 2-Propenoic acid, 2-[[5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxo octyl]-2-(1,1-dimethylethyl)phenoxy]methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-10-6 HCPLUS

CN Butanoic acid, 4-[5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxoethyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-11-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-12-8 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-13-9 HCPLUS
 CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-14-0 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-15-1 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-16-2 HCPLUS

CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-17-3 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-3-(3-chloro-2-hydroxypropoxy)-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 173334-18-4 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylthio)propoxy]- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 173334-19-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylsulfonyl)propoxy]- α -methyl- ζ -(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 173334-20-8 HCPLUS

CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[1-(methylsulfonyl)methoxy]-N-[3-(4-morpholinyl)propyl]-, monohydrochloride, (α R, γ S, δ S,.zeta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-37-7 HCPLUS

CN Acetic acid, [2-[(2S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173334-38-8 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173334-59-3 HCPLUS
 CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, dihydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 173335-47-2 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173335-48-3 HCPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, hydrochloride (1:2), (α S, δ S, γ S, ζ S)- (CA INDEX NAME)


Absolute stereochemistry.




• 2 HCl

RN 173335-49-4 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl- γ , η -dihydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-,
(α S,VS,8S,CS,9R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 173335-51-8 HCPLUS
CN Propanoic acid, 3-[5-[4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 173335-52-9 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl-3-(3-chloro-2-hydroxypropoxy)-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-
(CA INDEX NAME)



RN 173335-53-0 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylthio)propoxy]- α -methyl- ζ -(1-methylethyl)- (CA INDEX NAME)




RN 173335-54-1 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy-3-[2-hydroxy-3-(methylsulfonyl)propoxy]- α -methyl- ζ -(1-methylethyl)- (CA INDEX NAME)




RN 173335-56-3 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-3-(3-methoxypropoxy)- α , ζ ,4-tris(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173335-57-4 HCAPLUS
 CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α,ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173335-62-1 HCAPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-3-(3-methoxypropoxy)-4-[4-(methylamino)-4-oxobutyl]- α,ζ -bis(1-methylethyl)-N-(2-(4-morpholinyl)ethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173335-74-5 HCAPLUS
 CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α,ζ -bis(1-methylethyl)-N-[(2S)-5-oxo-2-pyrrolidinyl]methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173335-86-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-[(1,6-dihydro-6-oxo-2-pyridinyl)methyl]- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173335-92-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(4-methoxy-1-butenyl)- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173398-83-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-84-0 HCPLUS

CN 2-Naphthaleneoctanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-85-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-86-2 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2R,4R,5R,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-,

methyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




● HCl

RN 173398-87-3 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-88-4 HCPLUS

CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-89-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-,

monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-90-8 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-91-9 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-92-0 HCPLUS
 CN 2-Propenoic acid, 2-[(5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 173398-93-1 HCPLUS
 CN Butanoic acid, 4-[(5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-94-2 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -

hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-95-3 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-96-4 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-97-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-

dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-98-6 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173398-99-7 HCPLUS

CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173399-00-3 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173399-01-4 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 173399-21-8 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl- γ , η -dihydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-,
(α S, γ S, δ S, ζ S, n S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-24-1 HCAPLUS
 CN Benzenoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy-3-(3-methoxypropoxy)- α -, ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 173399-25-2 HCPLUS
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α R, γ S, δ S, ζ S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-26-3 HCAPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -


hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-27-4 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (α R, γ S,8S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-30-9 HCAPLUS
CN 2-Naphthalen-8-octanamide, δ -amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, (α R, γ S, $8S, .ze$ ta, S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-31-0 HCAPLUS
CN Benzenoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,3-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (4R,5S,8S,10S)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-32-1 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-33-2 HCPLUS
 CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-34-3 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-propenoxy)-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-35-4 HCPLUS
 CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 173399-36-5 HCPLUS
CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-37-6 HCPLUS
CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α R, γ S, δ S, ζ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-38-7 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-,
(α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



RN 173399-41-2 HCPLUS

CN 2-Propenoic acid, 2-[(5-[2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-43-4 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-44-5 HCPLUS

CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-45-6 HCPLUS


CN Acetic acid, [5-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-46-7 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173399-47-8 HCPLUS
 CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173399-48-9 HCPLUS
 CN Benzeneoctanamide, δ -amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-49-0 HCPLUS

CN Benzeneoctanamide, δ -amino-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-N-[3-(4-morpholinyl)propyl]-, (aR, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-66-1 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173399-67-2 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-31-2 HCPLUS

CN Benzeneoctanamide, δ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-, (aS, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-32-3 HCPLUS

CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-35-6 HCPLUS

CN Benzeneoctanamide, δ -amino- γ -hydroxy-4-methoxy-3-(4-methoxybutyl)- α , ζ -bis(1-methylethyl)-N-[(2R)-5-oxo-2-pyrrolidinyl]methyl]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-16-9 HCPLUS


CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- ζ -ethyl- γ -hydroxy- α -methyl-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-17-0 HCPLUS
 CN 2-Naphthaleneoctanamide, 8-amino-N-butyl- ζ -ethyl- γ -hydroxy- α -methyl-4-(propoxymethyl)-, (α S, γ S, δ S, .ze ta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-18-1 HCPLUS
 CN Benzeneoctanamide, 8-amino-N-butyl-4-(1,1-dimethylethyl)- γ ,2-dihydroxy- α -methyl- ζ -(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-19-2 HCPLUS
 CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 173521-20-5 HCPLUS
CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-21-6 HCPLUS
CN Benzeneoctanamide, δ -amino-3-(2-amino-2-oxoethoxy)-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173521-22-7 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(2-pyridinylmethoxy)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173521-23-8 HCPLUS
CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-(4-pyridinylmethoxy)-,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-24-9 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-25-0 HCPLUS

CN 2-Propenoic acid, 2-[(5-[(2S,4S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-26-1 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylthio)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-27-2 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(methylsulfonyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-28-3 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-29-4 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-30-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-3-[(2-nitrophenyl)methoxy]-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-31-8 HCPLUS

CN Benzenesoctanamide, 8-amino-3-[(2-aminophenyl)methoxy]-N-butyl-4-(1,1-dimethylethyl)- γ -hydroxy- α -methyl- ζ -(1-methylethyl)-, (aS, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-32-9 HCPLUS

CN Acetic acid, [2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173521-33-0 HCPLUS

CN Benzoic acid, 2-[(2S,4S,5S,7S)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-5-(1,1-dimethylethyl)-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 172900-94-6P 173336-00-0P 173336-05-5P
173336-08-8P 173336-09-9P 173336-10-2P
173336-11-3P 173336-24-8P 173336-72-6P
173336-73-7P 173337-05-8P 173337-09-2P
173337-10-5P 173337-11-6P 173337-12-7P
173337-13-8P 173337-14-9P 173337-15-0P
173337-16-1P 173337-17-2P 173337-18-3P
173337-19-4P 173337-20-7P 173337-21-8P
173337-22-9P 173337-23-0P 173337-24-1P
173338-39-1P 173400-41-4P 173400-42-5P
173400-43-6P 173400-47-0P 173400-48-1P
173400-49-2P 173400-50-5P 173400-51-6P
173400-52-7P 173400-53-8P 173400-54-9P
173400-55-0P 173400-56-1P 173400-57-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of δ -amino- γ -hydroxy- α -arylalkanoic acid amides as renin inhibitors)

RN 172900-94-6 HCPLUS

CN Carbanic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-00-0 HCPLUS

CN Carbanic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-05-5 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-2-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-08-8 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-09-9 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylthio)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-10-2 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-11-3 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2S)-2-hydroxy-3-(methylthio)propoxylphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-24-8 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(3-methoxypropoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-5-methyl-4-[[2-(4-morpholinyl)ethyl]amino]carbonyl]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-72-6 HCPLUS

CN Carbamic acid, N-[(1S,2S,4S)-2-hydroxy-1-[(2S)-2-[(4-methoxy-3-(4-methoxybutyl)phenyl)methyl]-3-methylbutyl]-5-methyl-4-[(2-(4-morpholinyl)ethyl)amino]carbonyl]hexyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173336-73-7 HCPLUS

CN Benzeneoctanamide, 8-azido-N-butyl- γ , η -dihydroxy-4-methoxy-3-[(2-methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-, (aS, γ S, δ S, ζ S, η R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-05-8 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-

dimethyllethyl)phenyl]methyl]butyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethyllethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-09-2 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethyllethyl)-3-(2-propenyl)oxy)phenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethyllethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-10-5 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethyllethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethyllethyl)phenoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173337-11-6 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethyllethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethyllethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-12-7 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(3-(2-amino-2-oxoethoxy)-4-(1,1-dimethylethyl)phenyl]methyl]-3-methylbutyl]-5-(butylamino)-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-13-8 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(2-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-14-9 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(4-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-15-0 HCPLUS

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-16-1 HCPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[[((1,1-dimethylethoxy)carbonyl)amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173337-17-2 HCPLUS

CN Butanoic acid, 4-[5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxo-4-oxo-4,5-dihydro-1H-1,3-dioxolane-2-yl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-18-3 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7R)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxo-4-oxo-4,5-dihydro-1H-1,3-dioxolane-2-yl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-19-4 HCPLUS


CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2-nitrophenyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-20-7 HCAPLUS

CN Carbamic acid, [5-(butylamino)-1-[2-[(4-(1,1-dimethylethyl)-3-(oxiranylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 173337-21-8 HCAPLUS

CN Carbamic acid, [5-(butylamino)-1-[2-[(4-(1,1-dimethylethyl)-2-(2-hydroxypropoxy)-3-(methylsulfonyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxypentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 173337-22-9 HCAPLUS

CN Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-

5-[{3-(4-morpholinyl)propyl}amino]-5-oxopentyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173337-23-0 HCAPLUS

141-73-0 25 °C (molar mass)

CN Carbamic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(3,3-dimethyl-2-oxobutoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl], 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173337-24-1 HCAPLUS

Carbamic acid, [(1S,2S,4R)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-hydroxyphenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-[(3-(4-morpholinyl)propyl)amino]-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




BN 173338-39-1 HCAPLUS

17353-59-1 (CA INDEX NAME)

Carbamic acid, N-[1-(1S,2S,4S)-4-[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-2-hydroxy-1-[(2S)-2-[(4-methoxy-3-(4-methoxybutyl)phenyl)methyl]-3-methylbutyl]-5-methylhexyl]-, 1,1-dimethylhexyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-41-4 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(methylthio)methoxy]phenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-42-5 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(methylsulfonyl)methoxy]phenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-43-6 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[[4-(1,1-dimethylethyl)-3-[(2R)-2-hydroxy-3-(methylthio)propoxylphenyl]methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-47-0 HCAPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 173400-48-1 HCAPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-49-2 HCAPLUS

CN Carbamic acid, [(1S,2S,4S)-1-[(2S)-2-[(3-(2-amino-2-oxoethoxy)-4-(1,1-dimethylethyl)phenyl)methyl]-3-methylbutyl]-5-(butylamino)-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-50-5 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(2-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-51-6 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(4-pyridinylmethoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-52-7 HCAPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(1-oxido-2-pyridinyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 173400-53-8 HCAPLUS

CN 2-Butenoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 173400-54-9 HCPLUS

CN Butanoic acid, 4-[5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-55-0 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-[(2-nitrophenyl)methoxy]phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-56-1 HCPLUS

CN Acetic acid, [5-[(2S,4S,5S,7S)-8-(butylamino)-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173400-57-2 HCPLUS

CN Carbamic acid, [(1S,2S,4S)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)-3-(3,5-dimethyl-2-oxobutoxy)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:995369 HCPLUS

DOCUMENT NUMBER: 124:145882

TITLE: Preparation of chiral 4-(oxotetrahydrofuryl)butyrate and analogs as antihypertensive intermediates

INVENTOR(S): Goechke, Richard; Herold, Peter; Rigollier, Pascal; Maibaum, Juergen Klaus

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 30 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678514	A1	19951025	EP 1995-810237	19950407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	A	19970225	US 1995-416237	19950404
US 5606078	A	19951019	FI 1995-1772	19950412
FI 9501772	A	19951019	NO 1995-1442	19950412
NO 9501442	A	19951019	AU 1995-16420	19950412
AU 9516420	A	19951026	CA 1995-2147052	19950413
CA 2147052	A1	19951019	HU 1995-1077	19950414
HU 72110	A2	19960328	JP 1995-92526	19950418
JP 08053434	A	19960227	US 1996-674555	19960702
US 5654445	A	19970805	US 1996-687878	19960725
US 5627182	A	19970506	US 1996-687277	19960725
US 5646143	A	19970708	US 1997-800671	19970214
US 5705658	A	19980106		

PRIORITY APPLN. INFO.:

CH 1994-1169
CH 1995-246
US 1995-416242
US 1996-687277A 19940418
A 19950130
A3 19950404
A3 19960725OTHER SOURCE(S):
GI

MARPAT 124:145882



I

AB Title compds. [I; R1 = (esterified) CO2H, CH2OH, CHO; R2,R4 = (cyclo)aliph, group, (hetero)arylaliph. group, etc.; R3 = N3, (aryl)aliphatic group-substituted NH2, protected NH2] were prepared as intermediates for antihypertensive amides. Thus, 1,4-dibromo-2-butene was dialkylated by 4(S)-benzyl-3-isovaleryloxazolidin-2-one and the brominated product treated with Bu4NN3 to give 3-[2(S)-[2(S)-azido-2(S)-4(S)-isopropyl-5-oxotetrahydrofuran-2(S)-yl]ethyl]-3-methylbutyryl]-4(S)-benzylloxazolidin-2-one which was treated with H2O2/LiOH to give 2(S)-[2(S)-azido-2(S)-[4(S)-isopropyl-5-oxotetrahydrofuran-2(S)-yl]ethyl]-3-methylbutyric acid.


IT 173154-08-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of chiral 4-(oxotetrahydrofuryl)butyrate and analogs as antihypertensive intermediates)

RN 173154-08-0 HCPLUS

CN Benzenoctanamide, δ -amino-N-butyl- γ -hydroxy-4-methoxy-3-[2-(methoxymethoxy)ethyl]- α , ζ -bis(1-methylethyl)-, (α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 173154-07-9P 173241-88-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral 4-(oxotetrahydrofuryl)butyrate and analogs as antihypertensive intermediates)

RN 173154-07-9 HCPLUS

CN Propanoic acid, 2-methyl-, 4-azido-7-[(butylamino)carbonyl]-5-hydroxy-1-[4-methoxy-3-[2-(methoxymethoxy)ethyl]phenyl]-8-methyl-2-(1-methylethyl)nonyl

ester, [1R-(1R*,2S*,4S*,5S*,7S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173241-88-8 HCPLUS

CN Propanoic acid, 2-methyl-, 4-azido-7-[(butylamino)carbonyl]-5-hydroxy-1-[4-methoxy-3-[2-(methoxymethoxy)ethyl]phenyl]-8-methyl-2-(1-methylethyl)nonyl ester, [1S-(1R*,2R*,4R*,5R*,7R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:995203 HCPLUS

DOCUMENT NUMBER: 124:117982

TITLE: Preparation of α -amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors.

INVENTOR(S): Goeschke, Richard

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 45 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 678500	A1	19951025	EP 1995-810238	19950407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5659065	A	19970819	US 1995-416240	19950404
FI 9501773	A	19951019	FI 1995-1773	19950412
NO 9501443	A	19951019	NO 1995-1443	19950412

AU 9516423	A 19951026	AU 1995-16423	19950412
CA 2147044	A1 19951019	CA 1995-2147044	19950413
JP 08027079	A 19960130	JP 1995-92827	19950418
US 5654445	A 19970805	US 1996-674555	19960702
US 5627182	A 19970506	US 1996-687878	19960725
US 5646143	A 19970708	US 1996-687277	19960725
US 5705658	A 19980106	US 1997-800671	19970214
PRIORITY APPLN. INFO.:		CH 1994-1169	A 19940418
		CH 1995-247	A 19950130
		US 1995-416242	A3 19950404
		US 1996-687277	A3 19960725

OTHER SOURCE(S): MARPAT 124:117982
GI



AB Title compds. [I; R1 = aliphatic, cycloaliphatic, aryl, heteroaryl, protected or etherified OH, etherified SH, etc.; R2 = aliphatic, cycloaliphatic, araliphatic, heteroaraliphatic, etc.; R1R2 = divalent aliphatic; R3 = (esterified) carboxy, formyl, hydroxymethyl; R4 = H, aliphatic, araliphatic, protecting group; R5 = H, aliphatic], were prepared. Thus, glycine anhydride was stirred 64 h with Et3OBF4 in CH2Cl2 to give 76% 3,6-dioxy-2,5-dihydropyrazine. The latter in THF at -40° was treated with BuLi and then with 2(R)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl bromide; the mixture was stirred 18 h at -20° to give 2(S)-[2(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methylbutyl]-3,6-dioxy-2,5-dihydropyran. This was stirred 30 min. with HCl in MeCN to give Et 2(S)-amino-4(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-5-methylhexanoate.


IT 172900-94-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of α -amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors)

RN 172900-94-6 HCPLUS

CN Carbanic acid, [(1S,2S,4R)-5-(butylamino)-1-[(2S)-2-[(4-(1,1-dimethylethyl)phenyl)methyl]-3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 172900-93-5P 173007-35-7P 173007-36-8P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of α -amino alcanoic acids and reduction products as
intermediates in the preparation of renin inhibitors)

RN 172900-93-5 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -
hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride,
(α R, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173007-35-7 HCPLUS

CN Benzeneoctanamide, δ -amino-N-butyl-4-(1,1-dimethylethyl)- γ -
hydroxy- α -methyl- ζ -(1-methylethyl)-, monohydrochloride,
(α S, γ S, δ S, ζ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173007-36-8 HCPLUS

CN Carbamic acid, [5-(butylamino)-1-[2-[[4-(1,1-dimethylethyl)phenyl]methyl]-
3-methylbutyl]-2-hydroxy-4-methyl-5-oxopentyl]-, 1,1-dimethylethyl ester,
[1S-[1R*(R*),2R*,4R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> FIL STNGUIDE
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY          SESSION
FULL ESTIMATED COST          97.54          659.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                              ENTRY          SESSION
CA SUBSCRIBER PRICE           -8.00          -8.00
```

FILE 'STNGUIDE' ENTERED AT 15:36:07 ON 26 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 21, 2008 (20080321/UP).

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

```
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY          SESSION
FULL ESTIMATED COST          1.50          660.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                              ENTRY          SESSION
CA SUBSCRIBER PRICE           0.00          -8.00
```

STN INTERNATIONAL LOGOFF AT 15:51:16 ON 26 MAR 2008